PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 69 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $164,000 | -2.4% | 23,303 | -2.5% | 0.09% | +335.0% |
| Q4 2019 | $168,000 | +33.3% | 23,900 | +136.6% | 0.02% | +233.3% |
| Q1 2019 | $126,000 | -80.2% | 10,100 | -89.3% | 0.01% | -86.4% |
| Q4 2018 | $636,000 | -55.5% | 94,600 | -31.8% | 0.04% | -46.3% |
| Q3 2018 | $1,428,000 | +53.7% | 138,800 | +0.4% | 0.08% | +51.9% |
| Q2 2018 | $929,000 | +32.5% | 138,300 | +69.3% | 0.05% | +20.0% |
| Q1 2018 | $701,000 | +56.8% | 81,700 | +280.0% | 0.04% | +87.5% |
| Q4 2017 | $447,000 | +10.9% | 21,500 | -31.7% | 0.02% | -4.0% |
| Q1 2017 | $403,000 | -41.8% | 31,500 | 0.0% | 0.02% | -56.1% |
| Q4 2016 | $692,000 | -22.2% | 31,500 | -25.2% | 0.06% | -20.8% |
| Q3 2016 | $889,000 | – | 42,100 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |